109082-85-1

Usage

Uses

Used in Pharmaceutical Industry:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is used as a pharmaceutical intermediate for the synthesis of various therapeutic agents. Its unique structure allows it to be modified and incorporated into a wide range of drug candidates, making it a valuable tool in the development of new medications.
Used in Research and Development:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is also used in research and development settings, where it can be studied for its potential biological activities and interactions with other molecules. Its complex structure and diverse functional groups make it an interesting subject for scientific investigation, potentially leading to new discoveries and applications in various fields.
Used in Impurity Analysis:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is used as an impurity in the analysis of Ganciclovir (G235000), a sugar-modified acyclic analogue of guanosine (G837900). Its presence as an impurity can help in understanding the purity and quality of Ganciclovir, ensuring the safety and efficacy of the drug.

Upstream product

• 82410-32-0 ganciclovir 
• 76-83-5 trityl chloride 

Downstream Products

• 1429306-18-2 C₅₂H₄₉N₅O₅ 
• 1429306-17-1 C₄₉H₄₃N₅O₅ 
• 88110-89-8 9-<(1-acetoxy-2-hydroxymethyl)ethoxymethyl>guanine 
• 175865-59-5 valganciclovir hydrochloride 
• 1219792-43-4 N-trytil-2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)methoxy-3-trityloxy-1'-propanyl-2'-(S)-azido-3'-methylbutanoate 
• 1219792-45-6 N,O-bistrityl-O-mesyl ganciclovir 
• 109061-20-3 Adamantane-1-carboxylic acid 2-[6-oxo-2-(trityl-amino)-1,6-dihydro-purin-9-ylmethoxy]-3-trityloxy-propyl ester 

Relevant academic research and scientific papers

Synthesis of valganciclovir hydrochloride congeners

Valganciclovir hydrochloride (1) is used for the treatment of cytomegalovirus (CMV) retinitis in patients with weakened immune systems. Valganciclovir hydrochloride is a hydrochloride salt of L-valyl ester of ganciclovir (2) that exists as a mixture of two diastereomers. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. During the process development of valganciclovir hydrochloride, six related substances (impurities) were observed along with the final active pharmaceutical ingredient. Among these six impurities, ganciclovir (2) and guanine (3) are the key starting materials and degraded impurities of ganciclovir, respectively. The remaining four impurities were identified as isovalganciclovir hydrochloride (4), methoxymethylguanine (5), O-acetoxy ganciclovir (6), and isovalarylganciclovir (7). The present work describes the synthesis and characterization of these four impurities.

A succinct synthesis of valganciclovir hydrochloride, a cytomegalovirus (CMV) retinitis inhibitor

A concise and efficient synthesis of valganciclovir hydrochloride 1, a CMV retinitis inhibitor, without involving protection-deprotection sequences, is described. The synthetic utility of (2S)-azido-3-methylbutyric acid, which acts as a masked L-valine equivalent, is demonstrated in the synthesis of 1. ARKAT-USA, Inc.

PREPARATION OF VALGANCICLOVIR AND ITS SALTS

Processes for preparing valganciclovir and pharmaceutically acceptable salts thereof, as well as intermediates for the processes.

Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative

Process for preparing the L-monovaline ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process provides an N,O-bis-trityl intermediate of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-